BeiGene gets NICE recommendation for Waldenström Macroglobulinemia therapy
Brukinsa is a small molecule BTK inhibitor being assessed for treating various B-cell malignancies.
Hematological Disorders
Latest in
Hematological Disorders
ESMO 2022: anti-CD25 mAbs—an exciting immunotherapy in the pipeline
Multiple studies have reported high levels of tumour-infiltrating regulatory T cells to correlate with adverse patient outcomes.
By
Rare Disease Spotlight-oncology therapies dominate the orphan drug landscape
The second edition of the Rare Disease Spotlight series investigates the trends in orphan drug designations across therapy areas over…
By
Novo Nordisk agrees to acquire biopharma firm Forma for $1.1bn
With the takeover, Novo Nordisk will also acquire etavopivat, a lead development candidate of Forma.
FDA accepts Sanofi’s haemophilia A treatment BLA for priority review
A new recombinant factor VIII therapy, efanesoctocog alfa is developed under a partnership between Sanofi and Sobi.
EC grants approval for BioMarin’s gene therapy to treat Hemophilia A
The approval is based on comprehensive data from Roctavian's clinical development programme.
UK NICE recommends Vifor’s Tavneos for AAV treatment
The recommendation is based on the complete development programme data, including findings from the Phase III ADVOCATE trial.
FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia
The approval is based on findings from two Phase III clinical trials and a long-term follow-up study of Zynteglo.